Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02296684 · ClinicalTrials.gov registry record · Phase 2
Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma
A Phase 2 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
NCT02296684 is a Phase 2 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 67 participants.
The verdict
NCT02296684, a Phase 2 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
Study Summary
The goal of this trial is to test the ability of MK-3475 (pembrolizumab) to improve locoregional recurrence and distant metastatic rates in high-risk patients with locally advanced head and neck squamous cell carcinomas (HNSCCs) that are treated with current standard of care surgical approaches.
Interventions
- DRUG Cisplatin
- PROCEDURE Surgery
- RADIATION Intensity modulated radiation therapy
- BIOLOGICAL MK-3475 (neoadjuvant)
- RADIATION Image-guided radiation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2015-03-25 |
| Est. Completion | 2025-07-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02296684
The ClinicalTrials.gov registry entry for NCT02296684 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cisplatin is the first listed.
NCT02296684 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02296684 about?
NCT02296684 is a clinical study titled "Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma". The goal of this trial is to test the ability of MK-3475 (pembrolizumab) to improve locoregional recurrence and distant metastatic rates in high-risk patients with locally advanced head and neck squamous cell carcinomas (HNSCCs) that are treated with current standard of care surgical approaches.
What is the current status of trial NCT02296684?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2015-03-25. Estimated completion is 2025-07-21.
What interventions are being tested in trial NCT02296684?
The interventions under investigation include: Cisplatin (DRUG), Surgery (PROCEDURE), Intensity modulated radiation therapy (RADIATION), MK-3475 (neoadjuvant) (BIOLOGICAL), Image-guided radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT02296684?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.